Tag

• UGI USER
• ALK-positive lung cancer cancer treatment breakthrough lung cancer therapy medical innovation oncology research Pfizer clinical results Pfizer Lorlatinib
• 65
• 0

“PFIZER’S LORLATINIB SHOWS PROMISING RESULTS FOR ADVANCED ALK-POSITIVE LUNG CANCER”

Why in the news? Pfizer’s drug Lorlatinib significantly reduces tumor progression and improves survival in advanced ALK-positive non-small cell lung cancer (NSCLC) patients. Trial results show more than half of patients on Lorlatinib did not see cancer progression after five years. source:healthline About Non-Small Cell Lung Cancer (NSCLC): Occurs when abnormal cells form and multiply …

Read More